Results 261 to 270 of about 208,301 (303)

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Molecular Cancer Therapeutics
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with significant morbidity and mortality and is projected to be the second leading cause of cancer-related deaths by 2030. Mutations in KRAS are found in the vast majority of PDAC cases and plays an important role in the development of the disease.
Minh T. Than, Mark O’Hara, Ben Z. Stanger, Kim A. Reiss   +3 more
openaire   +2 more sources

KRAS

2020
Daniela Furlan, Nora Sahnane
openaire   +1 more source

KRA

2021
openaire   +1 more source

Targeting the MAPK Pathway in KRAS-Driven Tumors

Cancer Cell, 2020
Matthias Drosten, Mariano Barbacid
exaly  

Redefining KRAS activation

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Cell, 2018
Chiara Ambrogio, Haiyun Wang, Marzia Capelletti   +2 more
exaly  

KRAS

2008
openaire   +1 more source

kra, n.

2023
openaire   +1 more source

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Cell, 2018
Lian-Sheng Li, Ulf Peters, Yuching Chen
exaly  

KRAS

2012
openaire   +1 more source